Kidney Week

Abstract: PO1026

Effect of Oral Supplementation with Curcumin in Diabetic Subjects with Proteinuric Kidney Disease: A Randomized Controlled Trial

Session Information

• Diabetic Kidney Disease: Clinical - 2
  October 22, 2020 | Location: On-Demand
  Abstract Time: 10:00 AM - 12:00 PM

Category: Diabetic Kidney Disease

• 602 Diabetic Kidney Disease: Clinical

Authors

• Hernandez Martinez, Ana Paulina, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Estado de Mexico, Mexico

Ana Paulina Hernandez Martinez,

• Cheng, Yao, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Estado de Mexico, Mexico

Yao Cheng,

• Gindl-Bracho, Alfonso, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Tlalpan, DF, Mexico

Alfonso Gindl-Bracho,

• Cabrera-Jara, Alejandro, Instituto Mexicano del Seguro Social, Ciudad de Mexico, DF, Mexico

Alejandro Cabrera-Jara,

• Fernandez Yepez, Ana Karen, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Estado de Mexico, Mexico

Ana Karen Fernandez Yepez,

• Martínez Hernández, María Fernanda, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Estado de Mexico, Mexico

María Fernanda Martínez Hernández,

• Sanchez-Lozada, L. Gabriela, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Estado de Mexico, Mexico

L. Gabriela Sanchez-Lozada,

• Tapia, Edilia, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Estado de Mexico, Mexico

Edilia Tapia,

• Castellanos, Francisco eugenio Rodriguez, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Estado de Mexico, Mexico

Francisco eugenio Rodriguez Castellanos,

• Vazquez-Rangel, Armando, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Estado de Mexico, Mexico

Armando Vazquez-Rangel,

• Madero, Magdalena, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, Estado de Mexico, Mexico

Magdalena Madero,

Background

Proteinuria remains one of the most important risk factors associated with kidney disease progression. Curcumin is a powerful antioxidant, and different studies have demonstrated the increased expression of cytoprotective proteins through the Keap1/NrF pathway. We conducted a randomized controlled trial in proteinuric diabetic patients to assess the effect of curcumin on proteinuria

Methods

The trial was conducted between May, 2016 and September, 2019. We included diabetic patients over 18 years of age, with an estimated GFR by CKD EPI > 15 ml/min/1.73 m2 and proteinuria > 1 gram/g despite optimal dose or contraindication to RAAS blockade. We excluded patients without DM, renal replacement therapy, kidney transplantation, or pregnancy. The study group received 3.22g of turmeric powder equivalent to 1.67g of curcumin, divided into three doses every 8 hours for 24 weeks. Primary outcome was proteinuria at the end of follow up. Secondary outcomes included eGFR and blood pressure control. Our power calculation estimated a total of 100 patients. Results were analyzed on an intention to treat basis

Results

100 diabetic patients were included. The mean age was 58.1 ± 10.3 years, 67% were female, 98% were hypertensive and the mean eGFR and 24h proteinuria were 35.9 ± 16.5 ml/min/1.73 m2 and 4.0±2.9 g/g, respectively. After 24 weeks of follow up, no significant differences were observed between groups for proteinuria, eGFR or blood pressure control (Table 1)

Conclusion

In this randomized double blinded controlled trial in diabetic subjects with nephrotic range proteinuria and moderate CKD, curcumin administration was not effective in proteinuria reduction or eGFR preservation. ClinicalTrials.gov Identifier: NCT03019848

Funding

• Government Support - Non-U.S.